American Heart Journal
Volume 148, Issue 6 , Pages 1012-1019 , December 2004

Acute ST-segment elevation myocardial infarction and prior stroke: An analysis from the Magnesium in Coronaries (MAGIC) trial

  • Howard A. Cooper, MD

      Affiliations

    • Washington Hospital Center, Washington, DC, USA
    • Corresponding Author InformationReprint requests: Howard A. Cooper, MD, Washington Hospital Center, 110 Irving Street NW, Suite NA1103, Washington, DC 20010, USA
    • ,
  • Michael J. Domanski, MD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Md, USA
    • ,
  • Yves Rosenberg, MD, MPH

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Md, USA
    • ,
  • James Norman, PhD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, Md, USA
    • ,
  • Judith H. Scott, RN, MPH

      Affiliations

    • New England Research Institutes, Watertown, Mass, USA
    • ,
  • Susan F. Assmann, PhD

      Affiliations

    • New England Research Institutes, Watertown, Mass, USA
    • ,
  • Sonja M. McKinlay, PhD

      Affiliations

    • New England Research Institutes, Watertown, Mass, USA
    • ,
  • Judith S. Hochman, MD

      Affiliations

    • New York University Medical Center, New York, NY, USA
    • ,
  • Elliott M. Antman, MD

      Affiliations

    • Brigham and Women's Hospital, Boston, Mass, USA
    • ,
  • the MAGIC Trial Investigators

Received 31 October 2003 ,Accepted 25 February 2004.

References 

  1. Hillis LD, Forman S, Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. J Am Coll Cardiol. 1990;16:313–315
  2. Lee KL, Woodlief LH, Topol EJ, et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction (results from an international trial of 41,021 patients. GUSTO-I Investigators). Circulation. 1995;91:1659–1668
  3. Morrow DA, Antman EM, Charlesworth A, et al.  TIMI risk score for ST-elevation myocardial infarction (a convenient, bedside, clinical score for risk assessment at presentation. An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial substudy). Circulation. 2000;102:2031–2037
  4. Tanne D, Gottlieb S, Caspi A, et al.  Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era (the Israeli Thrombolytic National Survey). Arch Intern Med. 1998;158:601–606
  5. Pfeffer MA, Moye LA, Braunwald E, et al.  Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA. 1991;266:528–532
  6. Ketley D, Woods KL. Selection factors for the use of thrombolytic treatment in acute myocardial infarction (a population based study of current practice in the United Kingdom. The European Secondary Prevention Study Group). Br Heart J. 1995;74:224–228
  7. Cupples LA, Gagnon DR, Wong ND, et al.  Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction. The Framingham Study. Am Heart J. 1993;125:863–872
  8. Cragg DR, Friedman HZ, Bonema JD, et al.  Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 1991;115:173–177
  9. The MAGIC Steering Committee . Rationale and design of the Magnesium in Coronaries (MAGIC) study (a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction). Am Heart J. 2000;139:10–14
  10. The Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002;360:1189–96
  11. Gore JM, Granger CB, Simoons ML, et al.  Stroke after thrombolysis (mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries). Circulation. 1995;92:2811–2818
  12. Ryan TJ, Antman EM, Brooks NH, et al.  1999 update (ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)). J Am Coll Cardiol. 1999;34:890–911
  13. Love BB, Grover-McKay M, Biller J, et al.  Coronary artery disease and cardiac events with asymptomatic and symptomatic cerebrovascular disease. Stroke. 1992;23:939–945
  14. Reicher-Reiss H, Jonas M, Tanne D, et al.  Prognostic significance of cerebrovascular disease in 11,526 chronic coronary artery disease patients. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol. 1998;82:1532–1535 A7
  15. Komrad MS, Coffey CE, Coffey KS, et al.  Myocardial infarction and stroke. Neurology. 1984;34:1403–1409
  16. Cotter G, Cannon CP, McCabe CH, et al.  Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes (are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study). Am Heart J. 2003;145:622–627

☆ Funding provide by National Heart, Lung, and Blood Institute (N01-8C-85155) of the National Institutes of Health, United States.

PII: S0002-8703(04)00402-8

doi: 10.1016/j.ahj.2004.02.017

American Heart Journal
Volume 148, Issue 6 , Pages 1012-1019 , December 2004

Article Tools

* Image Usage & Resolution